Lutropin Alpha
- Atc Codes:G03GA07
- CAS Codes:152923-57-4#56832-30-5#53664-53-2
- PHARMGKB ID:152923-57-4#56832-30-5#53664-53-2
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Luveris; Belgium: Luveris; Cyprus: Luveris; Czech Republic: Luveris; Denmark: Luveris; Estonia: Luveris; Finland: Luveris; France: Luveris; Germany: Luveris; Greece: Luveris; Hungary: Luveris; Ireland: Luveris; Italy: Luveris; Latvia: Luveris; Lithuania: Luveris; Luxembourg: Luveris; Malta: Luveris; Netherlands: Luveris; Poland: Luveris; Portugal: Luveris; Romania: Luveris; Slovakia: Luveris; Slovenia: Luveris; Spain: Luveris; Sweden: Luveris; UK: Luveris.
North America
Canada: Luveris; USA: Luveris.
Latin America
Argentina: Luveris; Mexico: Luver-I.S.
Drug combinations
Lutropin Alpha and Follitropin Alpha
Chemistry
Lutropin Alpha: C~437~H~682~N~122~O~134~S~13.~ Mw:10205.69 (α – subunit); C~577~H~929~N~165~O~161~S~14~ Mw: 13,202.49 (β-subunit). (1) Luteinizing hormone (human α-subunit reduced), complex with luteinizing hormone (human β-subunit reduced), glycoform α. CAS-152923-57-4; CAS-56832-30-5 (α-subunit); CAS-53664-53-2 (β-subunit)(2001).
Pharmacologic Category
Hormones and Synthetic Substitutes; Gonadotropins. Gonadotropin. Ovulation Stimulator. (ATC-Code: G03GA07).
Mechanism of action
Recombinant luteinizing hormone prepared using Chinese hamster cell ovaries. Increases follicular estradiol secretion.
Therapeutic use
Stimulation of follicular development in infertile hypogonadotropic hypogonadal women with profound luteinizing hormone deficiency. To be used in combination with follitropin alpha.
Pregnancy and lactiation implications
Contraindicated for use during pregnancy (increase in pre-/postimplantation loss observed in animal studies).
Unlabeled use
Contraindications
Hypersensitivity to lutropin alpha or any component of the formulation. Primary ovarian failure. Uncontrolled thyroid or adrenal dysfunction. Uncontrolled organic intracranial lesion. Abnormal uterine bleeding of undetermined origin. Ovarian cyst or enlargement of undetermined origin. Sex hormone-dependent tumors of reproductive tract and accessory organs. Pregnancy.
Warnings and precautions
Ovarian enlargement might be accompanied by abdominal distention or abdominal pain. Ovarian hyperstimulation syndrome (severe ovarian enlargement, abdominal pain/distention, nausea, vomiting, diarrhea, dyspnea, and oliguria; may be accompanied by ascites, pleural effusion, hypovolemia, electrolyte imbalance, hemoperitoneum, and thromboembolic events) might occur. Thromboembolic events reported. Use with caution in hepatic and renal impairment. Multiple births might result from use of these medications.